FDA Approves WEGOVY (semaglutide) for Cardiovascular Disease Prevention
In a significant stride towards combating cardiovascular disease (CVD), the U.S. Food and Drug Administration (FDA) recently approved WEGOVY (semaglutide), a novel medication demonstrating protective benefits against CVD. This milestone